At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Zilver® PTX® Drug-Eluting Peripheral Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zilver Paclitaxel(PTX) Thumbwheel Delivery System
In Brief
A clinical study evaluating Zilver® PTX® Drug-Eluting Peripheral Stent for Peripheral Vascular Disease. Completed, enrolled 40 participants across 6 sites in 3 countries.
Detailed Summary
The objective of this study is to evaluate the performance of the Zilver PTX stent thumbwheel delivery system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Vascular Disease
CountriesAustralia, Germany, New Zealand
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedOct 2014
Primary CompletionMay 2015
TodayJul 2026
First PostedOct 22, 2014
Enrollment StartSep 1, 2014
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.7 years ago
Interventions
Zilver® PTX® Drug-Eluting Peripheral Stentdevice
Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.